Royal Bank of Canada’s Mangoceuticals MGRX Stock Holding History

Royal Bank of Canada’s Portfolio MGRX Stock Details MGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-451	Closed	-$1K	–	7438
2025 Q3	$1K	Buy	+451	New	+$840	﹤0.01%	7004

Other funds holding MGRX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ACA

Ackerman Capital Advisors Dallas, Texas $497M AUM 16.31% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Royal Bank of Canada's MGRX Position: Q4 2025 in Review

Royal Bank of Canada sold out of Mangoceuticals (MGRX) in Q4 2025, closing a stake of 451 shares — an estimated $1K sold.

Royal Bank of Canada first reported a position in MGRX in Q3 2025 and held it in 1 quarter. The position peaked at $1K in Q3 2025. 18 funds tracked by Wall St. Rank hold MGRX as of Q4 2025.

Royal Bank of Canada reported no remaining Mangoceuticals position as of Q4 2025 after selling out during the quarter.
Royal Bank of Canada sold 451 Mangoceuticals shares in Q4 2025, an estimated $1K.
Royal Bank of Canada first reported a position in Mangoceuticals in Q3 2025 and held it in 1 quarter.
Royal Bank of Canada's Mangoceuticals position peaked at $1K in Q3 2025.
18 funds tracked by Wall St. Rank held Mangoceuticals as of Q4 2025.

Based on Royal Bank of Canada's 13F filing for Q4 2025, filed 17 Feb 2026.